

# BaroFeron™ - Multiple Sclerosis


## Overview / Indication:

BaroFold is developing a proprietary Interferon beta-1b for the treatment of Multiple Sclerosis (MS). MS is a progressive disorder of the central nervous system that affects approximately 2.5 million people worldwide with patients typically experiencing their first episode of MS between the ages of 20 and 40. BaroFeron will be differentiated from other interferon-beta products by improved safety and greater bioavailability enabled by BaroFold's proprietary PreEMT™ technology.

Attribute	TARGET PROFILE				
	Drug	*BaroFeron™	Betaseron®	Rebif®	Avonex®
High-dose, High-frequency		Yes	Yes	Yes	No
Efficacy		High	High	Medium	Low
Neutralizing Antibodies (persistent)		Low	High	Medium	Low
Tolerability		High	Low	Medium	High
Dosing Frequency		TBD	Every other day	3 times per week	Once a week
Reduces Disease Onset: Approved for use at first event		N/A	Yes	No	Yes

\* Drug Candidate not approved by FDA

Betaseron® is a registered trademark of Bayer Healthcare  
Avonex® is a registered trademark of Biogen Idec  
Rebif® is a registered trademark of EMD Serono



## Development Timeline

BaroFold is aggressively implementing its clinical and regulatory strategy in preparation for a rapid launch.

## Product Positioning

Interferon betas are considered the 'gold' standard of first line treatment options for managing the progression of MS. However, clinical evidence and physician surveys indicate that need exists to improve the efficacy and safety of these drugs.

In 2006, the world wide Interferon beta market generated over \$4 Billion in sales and is forecasted to reach over \$5B in 2010. BaroFeron is being developed as a 2nd generation interferon beta for relapsing remitting forms of MS with substantial opportunity to gain market share as a result of reduced neutralizing antibody prevalence and greater bioavailability, leading to greater efficacy. The delivery profile of BaroFeron should provide for fewer injection site reactions and a better tolerated product.

1745 38th Street • Boulder, CO 80301  
p: 303-926-0337 • f: 303-926-4292 • www.barofold.com

**BAROFOLD**  
IMPROVING PROTEIN THERAPEUTICS,  
IMPROVING PEOPLE'S LIVES